Can anyone verify this? Off Yahoo board

[jayfish101]

The NCCN updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include RYTELO in two major ways, both of which materially improve its commercial and clinical positioning.

All facts below are sourced from the NCCN‑related announcements.

Rytelo is now a Category 1 recommendation for second line treatment. Rytelo is the preferred standard after ESA Failure

Rytelo is now a Category 2A recommendation for first-line treatment in ESA-Ineligible patients both RS subtypes

[jayfish101]

From AI
the nccn updated its clinical practice guidelines in oncology for myelodysplastic syndromes (mds) to include rytelo in two major ways, both of which materially improve its commercial and clinical positioning. all facts below are sourced from the nccn‑related announcements. rytelo is now a category 1 recommendation for second line treatment. rytelo is the preferred standard after esa failure rytelo is now a category 2a recommendation for first-line treatment in esa-ineligible patients both rs subtypes
As of 2025, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Myelodysplastic Syndromes (MDS) include RYTELO (imetelstat) with the following high-level recommendations:
Category 1 Recommendation for Second-Line Treatment: RYTELO is recommended as a second-line therapy for symptomatic anemia in patients with lower-risk MDS.
For Ring Sideroblast-negative (RS-) patients: It is a Category 1 option after failure of erythropoiesis-stimulating agents (ESAs) or luspatercept (for those with serum EPO ≤500 mU/mL).
For Ring Sideroblast-positive (RS+) patients: It is a Category 1 option specifically after luspatercept failure (for those with serum EPO ≤500 mU/mL).
Category 2A Recommendation for First-Line Treatment: RYTELO is recommended as a first-line (frontline) option for patients who are ESA-ineligible, defined as having serum erythropoietin (EPO) levels >500 mU/mL. This applies to:
RS- subtypes who are unlikely to respond to immunosuppressive therapy.
RS+ subtypes.
Commercial and Clinical Positioning: These updates follow RYTELO's June 2024 FDA approval. The NCCN classification (Category 1 and 2A) reflects a uniform consensus (≥85%) among experts that the treatment is appropriate, strengthening its role as a standard of care following ESA failure.
For the most current official documentation, healthcare providers can access the NCCN Guidelines for Myelodysplastic Syndromes directly.

[jayfish101]

Is this HUGE?

[biopearl123]

These statements are true. We speculated in previous discussions “All roads lead to Rytello”. I think it’s fair to also speculate, the earlier in the course of the disease, the better. The concern has been that earlier treatment might encourage the emergence of more resistant clones, I am not sure this has been conclusively disproven but with the trends toward less transformation to AML clarity should come out in the wash.

[rccola335]

Can you see when these recommendations were made - it looks July of 24 to me

[biopearl123]

Last NCCN update meeting for MDS June 2025

[Ryan]

Apparently the updated version was published in October 2025:::
Per ChatGPT, which supplied a link that I could not copy from their app.

Here’s the most up-to-date info available on when the NCCN panel last met to update the Myelodysplastic Syndromes (MDS) guidelines — because these panels meet to review evidence and finalize guideline versions:

The most recent NCCN guideline version for MDS is Version 2.2026, which was released/updated in 2025 (later in the year, with the update logged as October 2025). That version reflects the latest formal panel deliberations and evidence review by the multidisciplinary NCCN MDS expert panel. 

NCCN panels (including the MDS panel) generally meet at least annually to review data and update recommendations. This strongly suggests the last full guideline update meeting happened in 2025, ahead of the Version 2.2026 publication. 

A couple points to keep in mind:
• The Version 2.2026 MDS guideline update reflects the latest consensus meeting and was finalized in late 2025.